U.S. aid tied to corporate interests could undermine local manufacturing, technology transfer, and long-term economic sovereignty in Nigeria.
Nigeria has made measurable progress in placing health at the centre of development. The Renewed Hope Agenda has elevated health as a priority, the Basic Health Care Provision Fund is strengthening primary care, and the Federal Ministry of Health and Social Welfare’s “Red Letter” campaign is empowering citizens to demand transparency. Health budget allocations have risen steadily from 2022 to 2025, signalling political intent, even though the Abuja Declaration target of 15 percent remains unmet.
Yet the recently signed U.S.–Nigeria Memorandum of Understanding (MoU) under the America First Global Health Strategy warrants scrutiny, not only for public accountability but also for its potential impact on Nigeria’s industrial and economic sovereignty. Branded as a $5.1 billion partnership over five years, with $3 billion from Nigeria and $2.1 billion from the U.S., the agreement covers disease surveillance, laboratory systems, outbreak response, health commodities, and expanded services. On paper, the numbers impress, but the terms matter far more for business and industrial policy.
The MoU was signed quietly before the Christmas holidays, and the text has not been made public. If Nigeria is contributing the largest share, why is transparency limited? Will these funds fall under existing accountability frameworks, such as the Health Sector-Wide Approach (SWAp) Joint Annual Reviews, or operate outside national oversight? Beyond process, the strategic implications are critical: the America First strategy explicitly ties U.S. health aid to American economic and national security interests, positioning Africa as a market for U.S. technologies and a source of strategic minerals.
For Nigerian business and manufacturing, the stakes are enormous. In 2025, Nigeria’s pharmaceutical market was valued at roughly $4.3 billion and projected to grow to $6.5 billion by 2030. Under the MoU, U.S. financing of 100 percent of Nigeria’s health commodities in 2026 risks prioritising American products, embedding foreign technologies as “market-shaping investments”. For instance, lenacapavir, a long-acting HIV prevention drug by U.S. company Gilead, has been positioned to secure early global market dominance. Its inclusion in bilateral agreements with countries like Mozambique and Eswatini risks locking public health cooperation into strategies that prioritise U.S. corporate market capture over national choice, affordability, and local manufacturing. This trajectory directly conflicts with Nigeria’s Presidential Initiative for Unlocking the Healthcare Value Chain (PVAC), established under the Renewed Hope Agenda to build local capacity to produce health commodities, including vaccines. COVID-19 demonstrated that health security is industrial security: reliance on imported products exposes Nigeria to supply shocks, foreign pricing decisions, and political volatility. Prioritizing U.S. corporate interests could undermine local manufacturing incentives, constrain industrial R&D, and weaken long-term economic sovereignty.
Data-sharing obligations embedded in the MoU further complicate the industrial picture. Requirements could extend for up to 25 years, granting foreign entities access to Nigerian pathogen and health system data with limited guarantees of local IP, production rights, or commercial benefit.
For government and industry leaders, the path forward is clear:
● Publish the MoU for legislative and public scrutiny to build investor confidence and ensure transparent decision-making.
● Align all bilateral cooperation with national economic, industrial, and health priorities, ensuring procurement decisions support domestic manufacturing and technology transfer.
● Protect local production by requiring technology transfer, local manufacturing quotas, and fair pricing in all procurement agreements.
● Renegotiate data-sharing terms to guarantee sovereign ownership, IP rights, and equitable access to innovations derived from Nigerian health data.
Business and economic stakeholders must ask: Will this deal stimulate domestic manufacturing and industrial growth, or primarily serve American corporate and geopolitical interests? Nigeria’s pharmaceutical, diagnostics, and health technology sectors represent billions in potential GDP contribution and jobs. Foreign dominance in procurement and R&D could divert these gains abroad, undermining both health security and economic opportunity.
The America First strategy is explicit: U.S. investments are a tool of national advantage. Nigeria does not need to reject cooperation; it must insist that such cooperation be on Nigerian terms, transparent, aligned with national priorities, and structured to strengthen local production and industrial sovereignty. Otherwise, the country risks “carrying last” while foreign markets and corporate interests reap the benefits of domestic investment.
Fadekemi Akinfaderin is a thought leader and public policy analyst with over 25 years of experience working in Nigeria and globally on health, gender equality, and development issues. She writes under the banner Make It Make Sense with Kemi (MIMS), a public analysis platform examining how power and policy shape people’s lives, with a focus on Nigeria and its global intersections.
